• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eisai restructures, cuts 180 jobs

Eisai restructures, cuts 180 jobs

December 2, 2013
CenterWatch Staff

Eisai’s R&D organization, Eisai Product Creation Systems (EPCS), is restructuring and will cut 180 jobs.

Previously, EPCS had a centralized management model within a single Core Function Unit (CFU) for clinical support functions worldwide. The new model has transferred those management responsibilities to other Product Creation Units/CFUs in order to streamline communications and decision making. Other key clinical support functions, such as those for statistical analysis and clinical pharmacology, have been placed under the direct jurisdiction of the chief clinical officer in an effort to further improve clinical success rates. The former Scientific and Operational Clinical Support (SOCS) CFU has also been dissolved as part of these changes.

Additionally, regarding drug discovery in neuroscience at Eisai's EMEA Knowledge Center (EKC) in the U.K., focus on the Open Innovation function, which primarily conducts joint research with University College London, has been increased, while the EKC's medicinal chemistry function has been dissolved.

To support advancements in Eisai's development pipeline, functions for small-molecule process development have been consolidated in Japan (Kashima, Tsukuba) and India (Vizag), while the related functions at the Andover, Mass., site have been dissolved. Andover will continue to serve as the discovery research hub in the U.S.

In order to further strengthen and promote development of biopharmaceuticals as next-generation drugs, the biopharmaceutical development functions that had been divided between research sites in the U.S. (Exton, Andover) have been consolidated into the newly established Biopharmaceutical Development Department, located at the Exton site.

The reorganizations will result in the reduction of approximately 130 positions in Europe and the U.S.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing